Poseida Therapeutics Inc
NASDAQ:PSTX
Income Statement
Earnings Waterfall
Poseida Therapeutics Inc
Revenue
|
64.7m
USD
|
Operating Expenses
|
-194.2m
USD
|
Operating Income
|
-129.5m
USD
|
Other Expenses
|
6.1m
USD
|
Net Income
|
-123.4m
USD
|
Income Statement
Poseida Therapeutics Inc
Jun-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
31
N/A
|
33
+4%
|
35
+8%
|
152
+329%
|
131
-14%
|
139
+7%
|
157
+12%
|
50
-68%
|
65
+30%
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(54)
|
(57)
|
(58)
|
(91)
|
(127)
|
(136)
|
(151)
|
(159)
|
(173)
|
(186)
|
(173)
|
(176)
|
(190)
|
(182)
|
(186)
|
(187)
|
(194)
|
|
Selling, General & Administrative |
(13)
|
(9)
|
(9)
|
(16)
|
(23)
|
(27)
|
(31)
|
(34)
|
(36)
|
(37)
|
(37)
|
(38)
|
(38)
|
(40)
|
(39)
|
(38)
|
(37)
|
|
Research & Development |
(35)
|
(40)
|
(49)
|
(76)
|
(104)
|
(109)
|
(120)
|
(126)
|
(137)
|
(148)
|
(147)
|
(150)
|
(153)
|
(142)
|
(146)
|
(149)
|
(157)
|
|
Other Operating Expenses |
(6)
|
(7)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
11
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(54)
N/A
|
(57)
-6%
|
(58)
-2%
|
(91)
-58%
|
(127)
-39%
|
(136)
-7%
|
(151)
-11%
|
(159)
-5%
|
(141)
+11%
|
(153)
-8%
|
(138)
+10%
|
(25)
+82%
|
(60)
-143%
|
(42)
+29%
|
(29)
+32%
|
(137)
-375%
|
(130)
+5%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
(2)
|
(2)
|
(2)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(3)
|
(4)
|
(4)
|
(5)
|
(6)
|
(7)
|
(8)
|
(8)
|
(9)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
20
|
11
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
1
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
3
|
6
|
8
|
14
|
15
|
|
Pre-Tax Income |
(55)
N/A
|
(57)
-5%
|
(59)
-3%
|
(94)
-58%
|
(130)
-39%
|
(139)
-7%
|
(155)
-11%
|
(163)
-5%
|
(125)
+23%
|
(145)
-16%
|
(142)
+2%
|
(29)
+80%
|
(64)
-120%
|
(44)
+31%
|
(29)
+35%
|
(131)
-358%
|
(123)
+6%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
0
|
0
|
(0)
|
(0)
|
|
Income from Continuing Operations |
(55)
|
(57)
|
(59)
|
(94)
|
(130)
|
(139)
|
(155)
|
(163)
|
(125)
|
(145)
|
(142)
|
(29)
|
(64)
|
(45)
|
(29)
|
(131)
|
(123)
|
|
Net Income (Common) |
(55)
N/A
|
(57)
-5%
|
(59)
-3%
|
(94)
-58%
|
(130)
-39%
|
(139)
-7%
|
(155)
-11%
|
(163)
-5%
|
(125)
+23%
|
(145)
-16%
|
(142)
+2%
|
(29)
+79%
|
(64)
-119%
|
(45)
+30%
|
(29)
+35%
|
(131)
-350%
|
(123)
+6%
|
|
EPS (Diluted) |
-0.89
N/A
|
-0.93
-4%
|
-0.96
-3%
|
-1.52
-58%
|
-2.1
-38%
|
-2.25
-7%
|
-2.5
-11%
|
-2.62
-5%
|
-2.01
+23%
|
-2.33
-16%
|
-2.28
+2%
|
-0.38
+83%
|
-0.89
-134%
|
-0.51
+43%
|
-0.33
+35%
|
-1.42
-330%
|
-1.37
+4%
|